CN Patent

CN1753912B — 抗pd-1抗体及其用途

Assigned to MedImmune Ltd · Expires 2011-11-02 · 15y expired

What this patent protects

本发明公开内容提供了能够作为PD-1(程序性死亡1)激动剂和/或拮抗剂的抗体和抗原结合片段，由此总体调节免疫应答，特别是由TcR和CD28介导的那些免疫应答。所公开的组合物及方法可用于例如治疗自身免疫病、炎性疾病、变态反应、移植物排斥、癌症以及其它免疫系统紊乱。

USPTO Abstract

本发明公开内容提供了能够作为PD-1(程序性死亡1)激动剂和/或拮抗剂的抗体和抗原结合片段，由此总体调节免疫应答，特别是由TcR和CD28介导的那些免疫应答。所公开的组合物及方法可用于例如治疗自身免疫病、炎性疾病、变态反应、移植物排斥、癌症以及其它免疫系统紊乱。

Drugs covered by this patent

Patent Metadata

Patent number
CN1753912B
Jurisdiction
CN
Classification
—
Expires
2011-11-02
Drug substance claim
No
Drug product claim
No
Assignee
MedImmune Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.